Results 161 to 170 of about 54,096 (328)

Extramedullary myeloid tumors in primary myelofibrosis [PDF]

, 1965
Philip Lieberman, Randi V. Rosvoll, Allyn B. Ley   +2 more
openalex   +1 more source

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

Haematologica, 2019
We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2). The study included 32 patients with polycythemia vera and 18 with primary
A. Sørensen, S. U. Mikkelsen, T. Knudsen, M. E. Bjørn, C. Andersen, O. Bjerrum, Nana Brochmann, D. Patel, L. R. Gjerdrum, D. El Fassi, T. Kruse, T. Larsen, H. T. Mourits-Andersen, C. Nielsen, C. Ellervik, N. Pallisgaard, M. Thomassen, L. Kjær, V. Skov, H. Hasselbalch   +19 more
semanticscholar   +1 more source

Ruxolitinib for Myelofibrosis [PDF]

New England Journal of Medicine, 2012
Steffen, Koschmieder, Adriane, Koppelle, Hans, Seifert   +2 more
openaire   +4 more sources

Prophylactic Vancomycin in the Primary Prevention of Clostridium difficile in Allogeneic Stem Cell Transplant

Transplant Infectious Disease, EarlyView.
Prophylactic oral vancomycin was associated with reduced Clostridium difficile infection in allogeneic stem cell transplant patients. No differences in hospital‐acquired infections, mortality, GVHD, or rehospitalization were observed. It is a low‐cost, effective preventative strategy, though further prospective studies are needed to confirm safety and ...
Brendon Fusco, Jasmine Tomita‐Barber, Natale Mazzaferro, Anne Tyno, Nicole McEntee, Patricia Greenberg, Roger Strair, Dale Schaar, Dennis Cooper   +8 more
wiley   +1 more source

Use of Testosterone and Busulfan in the Treatment of Myelofibrosis with Myeloid Metaplasia [PDF]

, 1964
Richard T. Silver, David Jenkins, Ralph L. Engle, Cynthia Q. Fuller   +3 more
openalex   +1 more source

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.

Blood, 2019
Anemia of lower-risk myelodysplastic syndromes (MDSs) and primary myelofibrosis (PMF) generally becomes resistant to available treatments, leading to red blood cell (RBC) transfusions, iron overload, shortened survival, and poor quality of life.
P. Fenaux, J. Kiladjian, U. Platzbecker
semanticscholar   +1 more source

Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced‐Intensity Fludarabine, Busulfan and Anti‐T‐Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy

European Journal of Haematology, Volume 115, Issue 1, Page 36-45, July 2025.
ABSTRACT Fludarabine, busulfan, and anti‐T‐lymphocyte globulin (FLUBU3+ATLG) reduced‐intensity conditioning is an established preparative regimen for allogeneic haematopoietic stem cell transplantation in older patients with myeloid malignancy. We examined its modern‐day performance in 175 sequentially treated patients on our national programme ...
Chris Armstrong, Eibhlin Conneally, Catherine Flynn, Paul Browne, Mairead Ni Chonghaile, Carmel Ann Galligan, Hayley Foy‐Stones, Nicola Gardiner, Greg Lee, Nina Orfali   +9 more
wiley   +1 more source

Effects of Splenectomy on Red-cell Production in Myelofibrosis [PDF]

, 1961
G. Wetherley‐Mein, N. F. Jones, Jack Pullan   +2 more
openalex   +1 more source

Clinicopathologic Characteristics and Prognostic Profile of Chronic Myeloid Neoplasms With Somatic NF1 Mutations in Adult Patients

European Journal of Haematology, Volume 115, Issue 1, Page 46-56, July 2025.
ABSTRACT Objectives The clinicopathologic and prognostic features of somatic NF1 mutations have been well studied in pediatric myeloid neoplasms and adult acute myeloid leukemia (AML) but not in adult chronic myeloid neoplasms (CMNs), including myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), and myelodysplastic/myeloproliferative ...
Hamza Tariq, Margarita Loxas, Mir B. Alikhan, Juehua Gao, Xinyan Lu, Qing Ching Chen, Yi‐Hua Chen, Jessica K. Altman, Lawrence J. Jennings, Madina Sukhanova   +9 more
wiley   +1 more source

TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 100, Issue S4, Page 88-115, June 2025.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53 mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source